louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06877091: Nutritional Status and Intake in Patients With Non-cystic Fibrosis Bronchiectasis (NCFB)
Official title: Nutritional Status and Intake in Patients With Non-cystic Fibrosis Bronchiectasis (NCFB) - a Cross Sectional Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Non Cystic Fibrosis Bronchiectasis
Keywords: Nutritional status
Dietary Intake
NCFB
Lead sponsor: University of Leeds
Sponsor class: OTHER
Collaborators: name: The Leeds Teaching Hospitals NHS Trust
First posted: 2025-03-14
Enrollment: 129
Sex: ALL
Minimum age (years): 17
Maximum age (years): 99
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Those who attend the Leeds Regional Bronchiectasis Clinic

Brief summary: The aim of this study was to characterise nutritional status and dietary intake in a population of individuals living with bronchiectasis from a regional clinic. Participants underwent usual assessment as per their standard pathway of care and in addition, body composition through skinfold measures, Handgrip strength and information on dietary intake over 3 days via 24 hour multiple pass recalls was also collected. This was to establish baseline measures and knowledge in support of understanding the impact of nutritional status within this group.


Eligibility criteria: Inclusion Criteria:

* People who have a confirmed diagnosis of NCFB
* people with NCFB who are clinically stable (not requiring acute admission to hospital)
* people who attend the regional clinic

Exclusion Criteria:

* People who are pregnant
* people with existing comorbidities such as malignancy

Primary outcomes:
measure: Lung Function (FEV1 )
timeFrame: At point of recruitment
measure: Lung Function ( FVC)
timeFrame: At point of recruitment
measure: Height (m)
timeFrame: At point of recruitment
measure: Weight (kg)
timeFrame: At point of recruitment
measure: BMI (kg/m2)
timeFrame: At point of recruitment
Secondary outcomes:
measure: Handgrip Dynamometry (kg/f)
timeFrame: At point of recruitment
measure: Tricep Skinfold measurement (mm)
timeFrame: At point of recruitment
measure: Dietary intake checklist
timeFrame: At point of recruitment
Other outcomes:
Locations:
city: Leeds
country: United Kingdom
facility: Leeds Teaching Hospitals Trust
state: West Yorkshire
Study officials:
References:
Clinical trial NCT03182491: Mechanisms of Anaphylaxis
Official title: Mechanisms of Anaphylaxis
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Anaphylaxis
Allergy
Transfusion Reaction
Febrile Transfusion Reaction
Keywords: Platelet activating factor
Basophil activation test
Anaphylatoxins
Lead sponsor: Haukeland University Hospital
Sponsor class: OTHER
First posted: 2017-06-09
Enrollment: 40
Sex: ALL
Minimum age (years): 16
Maximum age (years): 120
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults

Brief summary: The purpose of this study is to explore different mechanisms for anaphylaxis and find novel biomarkers for this hypersensitivity syndrome. The study participants are patients with anaphylaxis, patients with mild allergic reactions, and patients with febrile transfusion reactions. The investigators will also include a group of healthy controls.


Eligibility criteria: Inclusion Criteria:

According to the specific cohort:

1. Diagnosis of anaphylaxis
2. Mild allergic reaction
3. Febrile transfusion reaction
4. Healthy, no known allergic disease

Exclusion Criteria:

Suspicion or diagnosed sepsis Children

Primary outcomes:
measure: Clarify mechanisms for anaphylaxis and establish biomarkers for this syndrome
timeFrame: 2 days
Secondary outcomes:
Other outcomes:
Locations:
city: Bergen
country: Norway
facility: Haukeland University Hospital
Study officials:
affiliation: Haukeland University Hospital
name: Torunn O Apelseth, MD, PhD
role: STUDY_DIRECTOR
affiliation: Haukeland University Hospital
name: Morten Y Isaksen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03387891: Clinical Testing of the Cortrium C3 Device
Official title: Clinical Testing on Newly Developed Monitoring Technology (The Cortrium C3 Device) for Continuous Measurements of ECG, Respiratory Rate, Body Surface Temperature and Accelerometer Data for Patients With Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cancer
Lead sponsor: Cortrium
Sponsor class: INDUSTRY
Collaborators: name: University College Absalon
First posted: 2018-01-02
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with cancer diagnose admitted to the hospital for treatment and/or monitoring of their health condition.

Brief summary: Clinical data validation of the C3 device as a Vital Sign Monitoring System for patients under cancer treatment.

Detailed description: Cortrium has developed the C3 device. The C3 device contains sensors that monitors Electrocardiogram (ECG), Respiratory rate (breathes per minute), and Body surface temperature. Also, the C3 device contains an accelerometer for registration of the body posture.

The following thesis will be tested:

Thesis 1) Pulse: The C3 device produces clinically validated pulse data. Thesis 2) Respiratory rate: The C3 device produces clinically validated respiratory rate data (breaths per minute). Thesis 3) Infection: With no justified statistical significant correlation between skin and body temperature, the study is exploring how to prevent aggravated or lethal outcomes of cancer treatment, e.g. chemotherapy, by using vital signs measurements combined with accelerometer data to detect infection levels. Thesis 4) The qualitative study: The study will report the advantages and disadvantages regarding new technological solutions, and the change in workflow and healthcare provision as it is experienced by the healthcare personnel and the patients. The data validation studies (thesis 1-3) will be tested in comparison with golden standard measurements methods and/or data validated medical equipment.

Eligibility criteria: Inclusion Criteria:

* Legally competent persons - i.e., patients considered able to understand the information given about the clinical trial
* Person is 18 years or older
* Person has given a written informed consent

Exclusion Criteria:

* Not legally competent patients
* Pregnant and lactating women
* Fertile women, who do not use contraceptives
* Patients under 18 years
* Patients with known heart-related disease

Primary outcomes:
measure: Pulse rate
timeFrame: May 2017-March 2018
measure: Respiratory rate
timeFrame: May 2017-March 2018
Secondary outcomes:
measure: Infection
timeFrame: May 2017-March 2018
measure: Design & Workflow studies
timeFrame: May 2017-March 2018
Other outcomes:
Locations:
city: Lübeck
country: Germany
facility: University Medical Center Schleswig-Holstein, Campus Lübeck
state: Schleswig-Holstein
Study officials:
affiliation: Cortrium
name: Jacob Eric Nielsen, COO
role: STUDY_CHAIR
References:
Clinical trial NCT03447691: Comparison Between Volatile Anesthetic-desflurane and Total Intravenous Anesthesia With Propofol and Remifentanil on Early Recovery Quality and Long Term Prognosis of Patients Undergoing Pancreatic Cancer and Common Bile Duct Cancer Surgery
Official title: Comparison Between Volatile Anesthetic-desflurane and Total Intravenous Anesthesia With Propofol and Remifentanil on Early Recovery Quality and Long Term Prognosis of Patients Undergoing Pancreatic Cancer and Common Bile Duct Cancer Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pancreatic Cancer or Distal CBD Cancer
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2018-02-27
Enrollment: 132
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Investigators asses whether there is any difference in short term recovery and long term prognosis according to the anesthetic method in patients who undergoing pancreatic cancer and bile duct cancer and undergoing surgery for PPPD or distal pancreatectomy.


Eligibility criteria: Inclusion Criteria:

* Patients with ASA class I-III who are scheduled to undergo general anesthesia and who are diagnosed with pancreatic cancer or common bile duct cancer and who are scheduled for PPPD or distal pancreatectomy
* patients who voluntarily agree to participate the clinical study after fully informed and understood about the study

Exclusion Criteria:

* there was distant metastasis at the time of diagnosis
* history of drug adverse reaction or use of opioid or sedative drugs before the surgery
* patients who can not communicate enough to answer the survey
* obesity patients over BMI 30
* patient who are expected to maintain ventilator care on the first day of post operation due to the difficult to extubation right after the surgery
* patients who have inappropriate reasons to participate in clinical research

Primary outcomes:
measure: score of QoR40 (Quality of Recovery 40)
timeFrame: post operative day #3
Secondary outcomes:
measure: score of QoR40 (Quality of Recovery 40)
timeFrame: post operative day #1
measure: score of QoR40 (Quality of Recovery 40)
timeFrame: post operative day #7
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of Anesthesiology and Pain Medicine Anesthesia and Pain Research Institute Yonsei University College of Medicine
Study officials:
References:
citation: Joe YE, Kang CM, Lee HM, Kim KJ, Hwang HK, Lee JR. Quality of Recovery of Patients Who Underwent Curative Pancreatectomy: Comparison of Total Intravenous Anesthesia Versus Inhalation Anesthesia Using the QOR-40 Questionnaire. World J Surg. 2021 Aug;45(8):2581-2590. doi: 10.1007/s00268-021-06117-0. Epub 2021 Apr 21.
Clinical trial NCT00973791: Fluid Management for Cesarean Section II
Official title: Fluid Management for Cesarean Section Undergoing Spinal Anesthesia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cesarean Section
Keywords: Spinal anesthesia
Fluid therapy
Lead sponsor: Nanjing Medical University
Sponsor class: OTHER
Collaborators: name: Nanjing Maternity and Child Health Care Hospital
First posted: 2009-09-09
Enrollment: 860
Sex: FEMALE
Minimum age (years): 21
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Fluid management plays an essential role in cesarean section. In previous study (NCT00488111) the investigators found that prior-epidural anesthesia fluid management produced a more significant role in stabilizing the blood pressure and better prognosis after cesarean delivery than that of the posterior-anesthesia ones. Given epidural anesthesia has a time interval before reaching the best state of anesthesia, so the fluid management also has a relatively adequate time to resuscitation. In reality, spinal anesthesia is used popularly except for the epidural anesthesia, whereas spinal anesthesia would produce more significant fluctuation of the hemodynamics compared with the latter. Herein the investigators proposed whether the prior-spinal anesthesia fluid management also produced similar effect on hemodynamic characteristics to the epidural anesthesia.


Eligibility criteria: Inclusion Criteria:

* 21-40 yr
* First time of delivery
* ASA status I-II
* No premature
* No genetic and infectious diseases
* Chinese

Exclusion Criteria:

* \< 21 yr
* \> 40 yr
* Subjects with cardiac and pulmonary disorders
* Dislocation of placenta
* Pregnant hypertension
* Allergy to local anesthetics
* Unwilling to cooperation
* Need intraoperative administration of vascular active agents
* With significant delivery side effects

Primary outcomes:
measure: Rate of hypotension
timeFrame: Anesthesia begin (0 min) to 120 min after anesthesia
Secondary outcomes:
measure: Recurrence of hypotension after ephedrine or phenylephrine
timeFrame: Anesthesia begin (0 min) to 120 min after anesthesia
measure: Consumption of ephedrine and phenylephrine
timeFrame: Anesthesia begin (0 min) to 120 min after anesthesia
measure: Total volume of colloid or crystalloid
timeFrame: Fifteen minutes before anesthesia to 120 min after anesthesia
measure: One-min and 5-min Apgar scores
timeFrame: The first and fifth minute after cesarean successful delivery
measure: Oxygen saturation during hypotension
timeFrame: Anesthesia begin (0 min) to 120 min after anesthesia
measure: Duration of hypotension
timeFrame: Anesthesia begin (0 min) to 120 min after anesthesia
measure: Low umbilical cord pH (artery < 7.20)
timeFrame: At the time of successful delivery (0 min)
Other outcomes:
Locations:
city: Nanjing
country: China
facility: The Affiliated Nanjing Maternity and Child Health Care Hospital
state: Jiangsu
Study officials:
affiliation: Nanjing Medical University
name: XiaoFeng Shen, MD
role: STUDY_CHAIR
References:
Clinical trial NCT02206191: The Primary Care Obesity Network (PCON): Incorporating Principles of Self-regulation of Intake
Official title: The Primary Care Obesity Network (PCON): Incorporating Principles of Self-regulation of Intake
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Self-regulation
Lead sponsor: Nationwide Children's Hospital
Sponsor class: OTHER
Collaborators: name: Ohio State University
First posted: 2014-08-01
Enrollment: 120
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Mothers of 6-11 year olds being seen in primary care offices throughout Columbus, OH.

Brief summary: In response to the high prevalence rates of childhood obesity in central Ohio, the Center for Healthy Weight and Nutrition (CHWN) established the Primary Care Obesity Network (PCON); a partnership between primary care physicians and Nationwide Children's Hospital's Center for Healthy Weight and Nutrition, a tertiary care obesity center, the first of its kind in Ohio. The overall goal of PCON is to bring an effective and user friendly obesity management program to the community physician's office to prevent and treat the growing number of obese children in the setting of the private office. The predominant nutrition messaging approach to tackling childhood obesity has revolved around the food choices and portion sizes. While this is relevant, an area with significant potential for impact for maintaining optimal growth and a healthy weight for young children is addressing feeding behaviors and self-regulation of intake;. - the "how" of eating. The investigators objective it to investigate whether this self-regulation approach can be employed for an older age group of 6-11 years old.


Eligibility criteria: Inclusion Criteria:

* Mother of a 6-11 year old child

Exclusion Criteria:

* Unable to speak and read English

Primary outcomes:
measure: Examining use of disordered self-regulatory feeding behaviors, at survey completion
timeFrame: At survey completion, which will occur about 30 minutes after the survey is administered
Secondary outcomes:
Other outcomes:
Locations:
city: Columbus
country: United States
facility: Nationwide Children's Hospital
state: Ohio
Study officials:
affiliation: Nationwide Childrens Hospital, Columbus, Ohio
name: ihuoma Eneli, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06818591: Preventive Effect of H.Pylori Eradication on Osteoporosis
Official title: Preventive Effect of Helicobacter Pylori Eradication on Osteoporosis in Females: Prospective Observational Cohort Study for Up to 20 Years
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: HELICOBACTER PYLORI INFECTIONS
Osteoporosis
Keywords: Helicobacter pylori eradication
osteoporosis
Sex difference
Age
Lead sponsor: Seoul National University Bundang Hospital
Sponsor class: OTHER
First posted: 2025-02-10
Enrollment: 846
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients tested Helicobacter pylori status in Seoul National University Bundang Hospital, from 2003 to 2023

Brief summary: In this study, the investigators observed the long-term incidence rate of osteoporosis in patients who received Helicobacter pylori eradication and examined differences by age and sex.

Detailed description: In this study, the investigators observed the long-term incidence rate of osteoporosis in patients who received Helicobacter pylori eradication and examined differences by age and sex. In addition, the investigators will analyze the correlation between the incidence of osteoporosis by comparing confounding factors such as body mass index, steroid use, and proton pump inhibitor use as well as the eradication status of H. pylori.

Eligibility criteria: Inclusion Criteria:

ㆍPatients tested Helicobacter pylori status

Exclusion Criteria:

ㆍPatients aged \< 20 years ㆍPatients with unknown Helicobacter pylori bone density status ㆍPatients with with a history of gastric cancer ㆍPatients with prior Helicobacter pylori eradication therapy ㆍPatients with a history of osteoporosis

Primary outcomes:
measure: the incidence of new-onset osteoporosis
timeFrame: The patients were prospectively monitored until they either developed osteoporosis or reached the study endpoint in February 2023, whichever occurred first.
Secondary outcomes:
Other outcomes:
Locations:
city: Seongnam-si
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
state: Gyeonggi-do
Study officials:
References:
Clinical trial NCT03214991: Circulating Tumor DNA as a Prognostic Marker in Patients With Pancreatic Cancer
Official title: Circulating Tumor DNA as a Prognostic Marker in Patients With Pancreatic Cancer
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pancreatic Cancer
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2017-07-12
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients diagnosed with pancreatic cancer through EUS-FNA.

Brief summary: The aim of this study is to determine the usefulness of circulating tumor DNA as a prognostic factor in patients with pancreatic cancer.

Detailed description: There is currently no strong prognostic factor in pancreatic cancer. K-ras is the most commonly mutated gene in pancreatic cancer, with a mutation rate of 75% to 95%. These high mutation rates are expected to be useful for diagnosis and prognostic factors in future. Currently, K-ras mutation tests are often performed in tissues, and there are various limitations, in particular, limited obtaining of sufficient tissues. In this regard, analyzing the prognosis of pancreatic cancer through non-invasive blood testing has significant advantages. And Prognosis analysis through blood tests can be done through blood circulating tumor DNA. The relationship between prognosis and blood circulating tumor DNA has already been studied in other cancers such as colorectal cancer, and there have been several studies in pancreatic cancer. However, there are not many research results yet, and there are cases in which the results differ from study to study. Therefore, the purpose of this study is to compare the overall survival of patients with pancreatic cancer diagnosed by EUS-FNA according to the presence and amount of blood circulating tumor DNA with K-ras mutation.

Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with pancreatic cancer through EUS-FNA.

Exclusion Criteria:

* Severe mental illness
* Severe co-morbidity (ESRD, Advanced COPD, severe Heart failure, poorly controlled blood sugar)
* Pregnancy
* Patients who have received chemotherapy
* Coagulopathy

Primary outcomes:
measure: Overall survival rate
timeFrame: 48 months
Secondary outcomes:
measure: Overall survival rate according to the amount of blood circulating tumor DNA
timeFrame: 48mo
measure: K-ras mutation
timeFrame: 48 months
measure: Overall survival rate (EUS-FNA)
timeFrame: 48 months
measure: Overall survival rate (K-ras mutation type, circulating tumor DNA)
timeFrame: 48 months
measure: Overall survival rate (K-ras mutation type, EUS-FNA)
timeFrame: 48 months
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
state: Jongno-gu
Study officials:
affiliation: Seoul National University Hospital
name: Ji Kon Ryu, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04530591: User Acceptability of a Device-Based Opioid Overdose Intervention
Official title: A Proof of Concept, Randomized, Single Center Study on Frameworks for Wearable Devices to Sense and Respond to Opioid Overdoses
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Opioid Overdose
Opioid-use Disorder
Substance Use Disorders
Keywords: Naloxone Delivery
Survey
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
First posted: 2020-08-28
Enrollment: 97
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Study population is non-pregnant individuals over the age of 21 with opioid use disorder.

Brief summary: This pilot study evaluates the needs of opioid users for a device-based intervention for opioid overdoses. The results of this one-time short questionnaire will inform development of a novel naloxone delivery device.

Detailed description: All opioid overdose related deaths can be prevented with the timely delivery of Naloxone. This study is a one-time, preliminary survey of participants with opioid use disorder to assess the need for, and community attitudes towards, a wearable device capable of autonomously detecting and responding to an opioid overdose. The results of this survey will be used to guide ongoing development of a de novo device. This study will be conducted over a 3 month period and survey participants from the Kensington Neighborhood in North Philadelphia.

Eligibility criteria: Inclusion Criteria:

* Have used opioids for more than 3 months or will be having surgery where opioids will be administered

  * Able to provide informed consent
  * Moderate to severe chronic pain treated with opioids or recreational use

Exclusion Criteria:

* Pregnancy

Primary outcomes:
measure: Community Need for a Device-based Opioid Overdose Intervention
timeFrame: Day 1
Secondary outcomes:
measure: Functional and Aesthetic Preferences for Device-based Opioid Overdose Intervention
timeFrame: Day 1
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Prevention Point Philadelphia
state: Pennsylvania
Study officials:
affiliation: University of Pennsylvania
name: Jacob Brenner, MD/PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kanter K, Gallagher R, Eweje F, Lee A, Gordon D, Landy S, Gasior J, Soto-Calderon H, Cronholm PF, Cocchiaro B, Weimer J, Roth A, Lankenau S, Brenner J. Willingness to use a wearable device capable of detecting and reversing overdose among people who use opioids in Philadelphia. Harm Reduct J. 2021 Jul 23;18(1):75. doi: 10.1186/s12954-021-00522-3.